与类似-1的葡萄糖合使得向蛋白质降解成为可能
Liquan Zhu1, Yiyu Zhou1, Bei Zhang1
1Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China.
Bioorganic chemistry
|October 12, 2023
概括
新的葡萄糖类1受体向化基因 (GLP-1-LYTACs) 能够实现向蛋白质降解. 这种方法有效降解细胞外和细胞膜蛋白质,扩大了 lysosome-targeting 嵌合体的实用性.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- lysosome-targeting chimeras (LYTACs) 是一种针对细胞外蛋白的蛋白质降解技术.
- 像CI-M6PR和ASGPR这样的有限的溶酶体向受体 (LTR) 限制了LYTAC的应用.
- 扩大LTR连接物库对于更广泛的LYTAC框架开发至关重要.
研究的目的:
- 引入一种新型的LTR配体,葡萄糖样1 (GLP-1),用于向蛋白质降解.
- 开发和表征GLP-1受体向仿真体 (GLP-1-LYTACs).
- 评估GLP-1-LYTACs在降解各种细胞外和膜蛋白中的有效性.
主要方法:
- 使用点击化学,将GLP-1与向结合剂结合在一起,形成GLP-1-LYTACs.
- 利用GLP-1受体作为LTR用于向蛋白质到 lysosomes.
- 评估细胞外蛋白 (GFP,Neutravidin) 和细胞膜蛋白 (EGFR,PD-L1) 的降解情况.
主要成果:
- 通过将GLP-1与特定的结合剂结合,成功开发了GLP-1-LYTACs.
- 证明了细胞外蛋白质的有效溶解体降解,包括GFP和Neutravidin.
- 使用GLP-1-LYTACs展示了细胞膜蛋白质如EGFR和PD-L1的有效降解.
结论:
- GLP-1-LYTACs代表了针对蛋白质降解的新平台.
- 这种方法扩大了可向蛋白质的范围,包括细胞表面和分泌蛋白质.
- GLP-1-LYTAC系统为治疗性蛋白质分解策略提供了一个新的维度.
相关概念视频
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
Regulated Protein Degradation
7.4K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.4K
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274
The Proteasome
859
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
859


